Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Sleep Initiation and Maintenance Disorders: HELP
Articles from USA
Based on 2,297 articles published since 2008
||||

These are the 2297 published articles about Sleep Initiation and Maintenance Disorders that originated from USA during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. 2018

Bjerre, Lise M / Farrell, Barbara / Hogel, Matthew / Graham, Lyla / Lemay, Geneviève / McCarthy, Lisa / Raman-Wilms, Lalitha / Rojas-Fernandez, Carlos / Sinha, Samir / Thompson, Wade / Welch, Vivian / Wiens, Andrew. ·Assistant Professor in the Department of Family Medicine and in the School of Epidemiology and Public Health at the University of Ottawa in Ontario, Scientist in the C.T. Lamont Primary Health Care Research Centre of the Bruyère Research Institute, and Adjunct Scientist at the Institute for Clinical Evaluative Sciences (ICES). lbjerre@bruyere.org. · Assistant Professor in the Department of Family Medicine at the University of Ottawa, Adjunct Assistant Professor in the School of Pharmacy at the University of Waterloo in Ontario, and Scientist at the Bruyère Research Institute at the University of Ottawa. · Research Associate at the Bruyère Research Institute at the time of guideline development. · Medical Director of St Patrick's Home of Ottawa and Assistant Professor in the Department of Family Medicine at the University of Ottawa. · Assistant Professor of Medicine at the University of Ottawa, Chief of Geriatric Services at Hôpital Montfort, and a staff geriatrician with the Ottawa Hospital Division of Geriatrics. · Scientist at the Women's College Research Institute of Women's College Hospital in Toronto, Ont, and Assistant Professor with the Leslie Dan Faculty of Pharmacy and the Department of Family and Community Medicine at the University of Toronto. · Associate Professor and Associate Dean of Professional Programs in the Leslie Dan Faculty of Pharmacy at the University of Toronto at the time of guideline development. · Schlegel Research Chair in Geriatric Pharmacotherapy at the Schlegel-UW Research Institute on Ageing and the School of Pharmacy at the University of Waterloo at the time of guideline development. · Director of Geriatrics at Mount Sinai Hospital and the University Health Network hospitals in Toronto, Assistant Professor in the Department of Medicine, the Department of Family and Community Medicine, and the Institute for Health Policy, Management and Evaluation at the University of Toronto, and Assistant Professor in the Division of Geriatric Medicine and Gerontology at the Johns Hopkins University School of Medicine in Baltimore, MD. · Master's student in the School of Epidemiology and Public Health at the University of Ottawa at the time of guideline development. · Director of the Methods Centre at the Bruyère Research Institute and Assistant Professor in the School of Epidemiology and Public Health at the University of Ottawa at the time of guideline development. · Associate Professor and Head of the Division of Geriatric Psychiatry in the Department of Psychiatry at the University of Ottawa. ·Can Fam Physician · Pubmed #29358245.

ABSTRACT: OBJECTIVE: To develop an evidence-based guideline to help clinicians make decisions about when and how to safely taper and stop antipsychotics; to focus on the highest level of evidence available and seek input from primary care professionals in the guideline development, review, and endorsement processes. METHODS: The overall team comprised 9 clinicians (1 family physician, 1 family physician specializing in long-term care, 1 geriatric psychiatrist, 2 geriatricians, 4 pharmacists) and a methodologist; members disclosed conflicts of interest. For guideline development, a systematic process was used, including the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Evidence was generated from a Cochrane systematic review of antipsychotic deprescribing trials for the behavioural and psychological symptoms of dementia, and a systematic review was conducted to assess the evidence behind the benefits of using antipsychotics for insomnia. A review of reviews of the harms of continued antipsychotic use was performed, as well as narrative syntheses of patient preferences and resource implications. This evidence and GRADE quality-of-evidence ratings were used to generate recommendations. The team refined guideline content and recommendation wording through consensus and synthesized clinical considerations to address common front-line clinician questions. The draft guideline was distributed to clinicians and stakeholders for review and revisions were made at each stage. RECOMMENDATIONS: We recommend deprescribing antipsychotics for adults with behavioural and psychological symptoms of dementia treated for at least 3 months (symptoms stabilized or no response to an adequate trial) and for adults with primary insomnia treated for any duration or secondary insomnia in which underlying comorbidities are managed. A decision-support algorithm was developed to accompany the guideline. CONCLUSION: Antipsychotics are associated with harms and can be safely tapered. Patients and caregivers might be more amenable to deprescribing if they understand the rationale (potential for harm), are involved in developing the tapering plan, and are offered behavioural advice or management. This guideline provides recommendations for making decisions about when and how to reduce the dose of or stop antipsychotics. Recommendations are meant to assist with, not dictate, decision making in conjunction with patients and families.

2 Guideline Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. 2017

Sateia, Michael J / Buysse, Daniel J / Krystal, Andrew D / Neubauer, David N / Heald, Jonathan L. ·Geisel School of Medicine at Dartmouth, Hanover, NH. · University of Pittsburgh School of Medicine, Pittsburgh, PA. · University of California, San Francisco, San Francisco, CA. · Johns Hopkins University School of Medicine, Baltimore, MD. · American Academy of Sleep Medicine, Darien, IL. ·J Clin Sleep Med · Pubmed #27998379.

ABSTRACT: INTRODUCTION: The purpose of this guideline is to establish clinical practice recommendations for the pharmacologic treatment of chronic insomnia in adults, when such treatment is clinically indicated. Unlike previous meta-analyses, which focused on broad classes of drugs, this guideline focuses on individual drugs commonly used to treat insomnia. It includes drugs that are FDA-approved for the treatment of insomnia, as well as several drugs commonly used to treat insomnia without an FDA indication for this condition. This guideline should be used in conjunction with other AASM guidelines on the evaluation and treatment of chronic insomnia in adults. METHODS: The American Academy of Sleep Medicine commissioned a task force of four experts in sleep medicine. A systematic review was conducted to identify randomized controlled trials, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process was used to assess the evidence. The task force developed recommendations and assigned strengths based on the quality of evidence, the balance of benefits and harms, and patient values and preferences. Literature reviews are provided for those pharmacologic agents for which sufficient evidence was available to establish recommendations. The AASM Board of Directors approved the final recommendations. RECOMMENDATIONS: The following recommendations are intended as a guideline for clinicians in choosing a specific pharmacological agent for treatment of chronic insomnia in adults, when such treatment is indicated. Under GRADE, a STRONG recommendation is one that clinicians should, under most circumstances, follow. A WEAK recommendation reflects a lower degree of certainty in the outcome and appropriateness of the patient-care strategy for all patients, but should not be construed as an indication of ineffectiveness. GRADE recommendation strengths do not refer to the magnitude of treatment effects in a particular patient, but rather, to the strength of evidence in published data. Downgrading the quality of evidence for these treatments is predictable in GRADE, due to the funding source for most pharmacological clinical trials and the attendant risk of publication bias; the relatively small number of eligible trials for each individual agent; and the observed heterogeneity in the data. The ultimate judgment regarding propriety of any specific care must be made by the clinician in light of the individual circumstances presented by the patient, available diagnostic tools, accessible treatment options, and resources. We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use eszopiclone as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use zaleplon as a treatment for sleep onset insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use zolpidem as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use triazolam as a treatment for sleep onset insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use temazepam as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use ramelteon as a treatment for sleep onset insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use doxepin as a treatment for sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians not use trazodone as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians not use tiagabine as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians not use diphenhydramine as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians not use melatonin as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians not use tryptophan as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians not use valerian as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK).

3 Guideline Pharmacotherapy Treatment Options for Insomnia: A Primer for Clinicians. 2015

Asnis, Gregory M / Thomas, Manju / Henderson, Margaret A. ·Albert Einstein College of Medicine/Montefiore Medical Center, Department of Psychiatry & Behavioral Science, Bronx, NY 10467, USA. asnisarts@aol.com. · The Anxiety and Depression Clinic, Bronx, NY 10570, USA. asnisarts@aol.com. · The Anxiety and Depression Clinic, Bronx, NY 10570, USA. manju.thomas3@gmail.com. · The Anxiety and Depression Clinic, Bronx, NY 10570, USA. mahg96@aol.com. ·Int J Mol Sci · Pubmed #26729104.

ABSTRACT: Insomnia is a prevalent disorder with deleterious effects such as decreased quality of life, and a predisposition to a number of psychiatric disorders. Fortunately, numerous approved hypnotic treatments are available. This report reviews the state of the art of pharmacotherapy with a reference to cognitive behavioral therapy for insomnia (CBT-I) as well. It provides the clinician with a guide to all the Food and Drug Administration (FDA) approved hypnotics (benzodiazepines, nonbenzodiazepines, ramelteon, low dose sinequan, and suvorexant) including potential side effects. Frequently, chronic insomnia lasts longer than 2 years. Cognizant of this and as a result of longer-term studies, the FDA has approved all hypnotics since 2005 without restricting the duration of use. Our manuscript also reviews off-label hypnotics (sedating antidepressants, atypical antipsychotics, anticonvulsants and antihistamines) which in reality, are more often prescribed than approved hypnotics. The choice of which hypnotic to choose is discussed partially being based on which segment of sleep is disturbed and whether co-morbid illnesses exist. Lastly, we discuss recent label changes required by the FDA inserting a warning about "sleep-related complex behaviors", e.g., sleep-driving for all hypnotics. In addition, we discuss FDA mandated dose reductions for most zolpidem preparations in women due to high zolpidem levels in the morning hours potentially causing daytime carry-over effects.

4 Guideline A practice pathway for the identification, evaluation, and management of insomnia in children and adolescents with autism spectrum disorders. 2012

Malow, Beth A / Byars, Kelly / Johnson, Kyle / Weiss, Shelly / Bernal, Pilar / Goldman, Suzanne E / Panzer, Rebecca / Coury, Daniel L / Glaze, Dan G / Anonymous1500741. ·Departments of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. beth.malow@vanderbilt.edu ·Pediatrics · Pubmed #23118242.

ABSTRACT: OBJECTIVE: This report describes the development of a practice pathway for the identification, evaluation, and management of insomnia in children and adolescents who have autism spectrum disorders (ASDs). METHODS: The Sleep Committee of the Autism Treatment Network (ATN) developed a practice pathway, based on expert consensus, to capture best practices for an overarching approach to insomnia by a general pediatrician, primary care provider, or autism medical specialist, including identification, evaluation, and management. A field test at 4 ATN sites was used to evaluate the pathway. In addition, a systematic literature review and grading of evidence provided data regarding treatments of insomnia in children who have neurodevelopmental disabilities. RESULTS: The literature review revealed that current treatments for insomnia in children who have ASD show promise for behavioral/educational interventions and melatonin trials. However, there is a paucity of evidence, supporting the need for additional research. Consensus among the ATN sleep medicine committee experts included: (1) all children who have ASD should be screened for insomnia; (2) screening should be done for potential contributing factors, including other medical problems; (3) the need for therapeutic intervention should be determined; (4) therapeutic interventions should begin with parent education in the use of behavioral approaches as a first-line approach; (5) pharmacologic therapy may be indicated in certain situations; and (6) there should be follow-up after any intervention to evaluate effectiveness and tolerance of the therapy. Field testing of the practice pathway by autism medical specialists allowed for refinement of the practice pathway. CONCLUSIONS: The insomnia practice pathway may help health care providers to identify and manage insomnia symptoms in children and adolescents who have ASD. It may also provide a framework to evaluate the impact of contributing factors on insomnia and to test the effectiveness of nonpharmacologic and pharmacologic treatment strategies for the nighttime symptoms and daytime functioning and quality of life in ASD.

5 Guideline Clinical guideline for the evaluation and management of chronic insomnia in adults. 2008

Schutte-Rodin, Sharon / Broch, Lauren / Buysse, Daniel / Dorsey, Cynthia / Sateia, Michael. ·Penn Sleep Centers, University of Pennsylvania Health System, Philadelphia, PA 19104, USA. rodins@hphs.upenn.edu ·J Clin Sleep Med · Pubmed #18853708.

ABSTRACT: Insomnia is the most prevalent sleep disorder in the general population, and is commonly encountered in medical practices. Insomnia is defined as the subjective perception of difficulty with sleep initiation, duration, consolidation, or quality that occurs despite adequate opportunity for sleep, and that results in some form of daytime impairment.1 Insomnia may present with a variety of specific complaints and etiologies, making the evaluation and management of chronic insomnia demanding on a clinician's time. The purpose of this clinical guideline is to provide clinicians with a practical framework for the assessment and disease management of chronic adult insomnia, using existing evidence-based insomnia practice parameters where available, and consensus-based recommendations to bridge areas where such parameters do not exist. Unless otherwise stated, "insomnia" refers to chronic insomnia, which is present for at least a month, as opposed to acute or transient insomnia, which may last days to weeks.

6 Editorial The power of pooled analyses to inform about the effects of CBTI on outcomes beyond sleep. 2019

Manber, Rachel. ·Department of Psychiatry and Behavioral Sciences, Stanford University, USA. ·Sleep Med Rev · Pubmed #30691658.

ABSTRACT: -- No abstract --

7 Editorial The Insomniac's Kidney-A Novel Perspective on Renal Dysfunction. 2018

Covassin, Naima / Somers, Virend K. ·Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. · Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. Electronic address: somers.virend@mayo.edu. ·Mayo Clin Proc · Pubmed #30392538.

ABSTRACT: -- No abstract --

8 Editorial What should we tell our worried patients with insomnia about blood pressure? 2018

Fernandez-Mendoza, Julio. ·Sleep Research & Treatment Center, Penn State College of Medicine, Penn State Health Milton S. Hershey Medical Center, 500 University Dr. H073, Hershey, PA, 17033, USA. Electronic address: jfmendoza@psu.edu. ·Sleep Med Rev · Pubmed #30097172.

ABSTRACT: -- No abstract --

9 Editorial Comorbid insomnia and sleep apnea: a prevalent but overlooked disorder. 2018

Brock, Matthew S / Mysliwiec, Vincent. ·Department of Sleep Medicine, San Antonio Military Medical Center, 1100 Wilford Hall Loop, Bldg 4554, JBSA-Lackland, TX, 78236, USA. · Department of Sleep Medicine, San Antonio Military Medical Center, 1100 Wilford Hall Loop, Bldg 4554, JBSA-Lackland, TX, 78236, USA. Vincent.mysliwiec.mil@mail.mil. ·Sleep Breath · Pubmed #29372382.

ABSTRACT: -- No abstract --

10 Editorial Cognitive behavioral therapy for insomnia (CBT-I): What is known, and advancing the science by avoiding the pitfalls of the placebo effect. 2018

McCall, William V. ·Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University, 997 St Sebastian Way, Augusta, 90912, Georgia. Electronic address: wmccall@augusta.edu. ·Sleep Med Rev · Pubmed #28655580.

ABSTRACT: -- No abstract --

11 Editorial Connecting insomnia, sleep apnoea and depression. 2017

Grandner, Michael A / Malhotra, Atul. ·Sleep and Health Research Program, Department of Psychiatry, University of Arizona College of Medicine, Tucson, Arizona, USA. · Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California San Diego, San Diego, California, USA. ·Respirology · Pubmed #28556352.

ABSTRACT: -- No abstract --

12 Editorial Insomnia in the Cancer Patient: A Complex Problem. 2017

Mahtani, Reshma L. ·Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System, Deerfield Beach, Florida. ·Breast J · Pubmed #28295839.

ABSTRACT: -- No abstract --

13 Editorial Payer Perspective of the American Academy of Sleep Medicine Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia. 2017

Sateia, Michael J / Sherrill, William C / Winter-Rosenberg, Carolyn / Heald, Jonathan L. ·Geisel School of Medicine at Dartmouth, Hanover, NH. · Presbyterian Sleep Medicine, Huntersville, NC. · American Academy of Sleep Medicine, Darien, IL. ·J Clin Sleep Med · Pubmed #28095976.

ABSTRACT: -- No abstract --

14 Editorial Should we finally include quantitative criteria in our definition of insomnia? 2016

Edinger, Jack D. ·Division of Pulmonology, Critical Care and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, CO, USA. Electronic address: edingerj@njhealth.org. ·Sleep Med · Pubmed #27838238.

ABSTRACT: -- No abstract --

15 Editorial An Update on Sleep and Sedation Issues in Critical Care. 2016

Foster, Jan. ·Nursing Inquiry and Intervention, Inc, The Woodlands, TX 77381, USA. Electronic address: jgwfoster@comcast.net. ·Crit Care Nurs Clin North Am · Pubmed #27215363.

ABSTRACT: -- No abstract --

16 Editorial Integrative medicine: A primer. 2015

Hillinger, Marni G. ·Department of Physical Medicine and Rehabilitation , Osher Center for Integrative Medicine at Vanderbilt , Nashville, TN, USA. ·Cranio · Pubmed #26825193.

ABSTRACT: -- No abstract --

17 Editorial A commentary on the "Functioning of three attentional networks and vigilance in primary insomnia". 2015

Perlis, Michael L / Roalf, David R / Kloss, Jaqueline D. ·Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania, USA. Electronic address: mperlis@upenn.edu. · Neuropsychiatry Section, Department of Psychiatry, University of Pennsylvania, USA. · Department of Psychology, Drexel University, USA. ·Sleep Med · Pubmed #26459678.

ABSTRACT: -- No abstract --

18 Editorial Insomnia symptoms predict physical and mental impairments among postmenopausal women. 2015

Grandner, Michael A / Nowakowski, Sara / Kloss, Jacqueline D / Perlis, Michael L. ·Behavioral Sleep Medicine Program, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Center for Sleep and Circadian Neurobiology, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: grandner@gmail.com. · Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, USA. · Department of Psychology, Drexel University, Philadelphia, PA, USA. · Behavioral Sleep Medicine Program, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Center for Sleep and Circadian Neurobiology, University of Pennsylvania, Philadelphia, PA, USA. ·Sleep Med · Pubmed #25698406.

ABSTRACT: -- No abstract --

19 Editorial What if? 2015

McCall, W Vaughn. ·From the Department of Psychiatry and Health Behavior, Georgia Regents University, Augusta, GA. ·J ECT · Pubmed #25627212.

ABSTRACT: -- No abstract --

20 Editorial Resilience and readiness through restorative sleep. 2015

Germain, Anne. ·Department of Psychiatry and Psychology, University of Pittsburgh, Pittsburgh, PA. ·Sleep · Pubmed #25581926.

ABSTRACT: -- No abstract --

21 Editorial The brave new world of healthcare delivery: just where are we in our understanding of e-health methods for insomnia and depression management? 2015

Edinger, Jack D. ·Division of Pulmonology, Critical Care and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, CO; Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC. ·Sleep · Pubmed #25581925.

ABSTRACT: -- No abstract --

22 Editorial A step towards stepped care: delivery of CBT-I with reduced clinician time. 2015

Manber, Rachel / Simpson, Norah S / Bootzin, Richard R. ·Department of Psychiatry and Behavioral Sciences, Stanford University, 401 Quarry Road, Stanford, CA 94301-5597, USA. Electronic address: Rmanber@stanford.edu. · Department of Psychiatry and Behavioral Sciences, Stanford University, 401 Quarry Road, Stanford, CA 94301-5597, USA. · Department of Psychology, University of Arizona, USA. ·Sleep Med Rev · Pubmed #25454675.

ABSTRACT: -- No abstract --

23 Editorial Sleep medication failure and newly diagnosed obstructive sleep apnea: the role of brain function modulation by muscle afferent activity. 2014

Lanier, William L / Ramar, Kannan. ·Department of Anesthesiology, Mayo Clinic, Rochester, MN. Electronic address: lanier.william@mayo.edu. · Division of Pulmonary and Critical Care Medicine, and the Center for Sleep Medicine, Mayo Clinic, Rochester, MN. ·Mayo Clin Proc · Pubmed #25467642.

ABSTRACT: -- No abstract --

24 Editorial Improve sleep during midlife: address mental health problems early. 2014

Conroy, Deirdre A. ·Department of Psychiatry, University of Michigan, Ann Arbor, MI. ·Sleep · Pubmed #25364068.

ABSTRACT: -- No abstract --

25 Editorial From the guest editor: the search for sleep and energy: addressing the needs of cancer patients who suffer from insomnia and fatigue. 2014

Kapo, Jennifer. ·From the Palliative Care Service, Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT. ·Cancer J · Pubmed #25299137.

ABSTRACT: -- No abstract --

Next